ERBB2 and breast cancer: A nearly significant association was also noted between MetaSite Score and breast cancer specific survival (p = 0.06) but not overall survival (OS) (p = 0.21) in the HR+/HER2- group in the time-varying coefficient model, which may be explained by the high proportion of deaths in this group that were not due to breast cancer (48/85 [56%]).